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ABSTRACT
The OncoDB.HCC (http://oncodb.hcc.ibms.sinica.
edu.tw) is based on physical maps of rodent and
human genomes containing quantitative trait loci
of rodent HCC models and various human HCC
somatic aberrations including chromosomal data
from loss of heterozygosity and comparative gen-
ome hybridization analyses, altered expression of
genes from microarray and proteomic studies, and
finally experimental data of published HCC genes.
Comprehensive integration of HCC genomic aberra-
tion data avoids potential pitfalls of data inconsis-
tency from single genomic approach and provides
lines of evidence to reveal somatic aberrations from
levels of DNA, RNA to protein. Twenty-nine of
30 (96.7%) novel HCC genes with significant altered
expressions in compared between tumor and adja-
cent normal tissues were validated by RT–PCR in
45 pairs of HCC tissues and by matching expression
profiles in 57 HCC patients of re-analyzed Stanford
HCC microarray data. Comparative mapping of HCC
loci in between human aberrant chromosomal
regions and QTLs of rodent HCC models revealed
12 syntenic HCC regions with 2 loci effectively
narrowed down to 2 Mb. Together, OncoDB.HCC
graphically presents comprehensive HCC data inte-
gration, reveals important HCC genes and loci for
positional cloning and functional studies, and dis-
closes potential molecular targets for improving HCC
diagnosis and therapy.
INTRODUCTION
Cancer is a heterogeneous genetic disease of somatic cells
arising from accumulated genetic changes on cancer genome
resulted in alterations of gene expression, unregulated cell
growth and triggering formation of malignant neoplasm.
Systematic genomic approaches have been applied to dissect
tumorigenic pathways for diagnostic and prognostic applica-
tions and to search for potential cancer genes as therapeutic
targets. These technologies revealed a global view of cancer
genomic aberrations including loss of heterozygosity (LOH)
and comparative genomic hybridization (CGH) analyses to
identify chromosome aberrations as well as microarray and
proteomic analyses to proﬁle the alteration of cancer gene
expression. It has been proposed that there are four to
seven somatic aberrations occurred at the rate-limiting steps
during epithelial tumor progression including six categories
of essential alterations in cell physiology that collectively
perturb regulatory circuits of normal cell proliferation and
homeostasis leading to malignant growth (1). Since multiple
signaling pathways might be disrupted at different points in
different cancers and since aberration of mutator genes
could promote the genome instability during cancer develop-
ment, the patterns of genetic aberrations tend to be non-
random but differ between cancers of different tissues and
of different subtypes from the same tissue.
Toward accelerating our understanding of tumorigenesis
for better management of cancer patients, genomic appro-
aches for systematically measuring somatic altered cancer
genome and gene expression should be critical for clinical
applications such as diagnosis, prognosis, classifying cancer
subtypes and options of therapeutic treatment (2,3). However,
identiﬁcation of putative cancer gene is still hampered by the
difﬁculty of further reﬁning the precise aberrant region owing
to the low resolution of chromosome alterations detected by
CGH and the large deletions of LOH detected by microsatel-
lite markers (4). In addition, the noisy data of chromosome
aberrations and inconsistent results of altered gene expression
detected by microarray and proteomic experiments, further
demonstrated an emergent need of integrating qualiﬁed can-
cer genomic and expression data for developing new and
effective cancer therapeutic targets. (5–8)
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doi:10.1093/nar/gkl845Human hepatocellular carcinoma (HCC) is the sixth most
common cancer worldwide and the third most common
cause of cancer death with prevalent areas in Asia and
sub-Saharan Africa. (9) Although recent studies suggested
increase of HCC incidence in western countries, >80% of
the HCC cases occurred in above endemic areas are owing
to exposure of major risk factors such as hepatitis viruses,
mycotoxins and alcohol abuse. (10) Since HCC progression
is usually asymptomatic resulted in poor prognosis and low
5-year survival rate (12–15%), comprehensive molecular
genetic studies will be important for improving clinical man-
agement of HCC. Previous studies by our group and others
have already conducted experiments of genome-wide LOH,
CGH, microarray and proteomic analyses (11–14). Compre-
hensive analysis further allowed us to reveal two major
genetic pathways, genome stable and instable pathways, in
HCC progression. We therefore selected HCC as a cancer
model to construct a public accessible integrated database,
OncoDB.HCC, with user-friendly and graphically displayed
interfaces as useful resources for facilitating researches in
HCC tumorigenesis.
RESULTS
Construction of OncoDB.HCC
As indicated in Figure 1, the chromosome view interface
demonstrates the main features of the database. The HCC
data are constructed based on physical maps of human and
rodent genome sequences from Ensembl and illustrated in
several aspects including cancer genomic aberration data of
LOH and CGH studies, altered gene expression in transcrip-
tomes and proteomes analyses, genes with experimental data
in HCC tissues reported in PubMed articles and the QTLs of
rodent HCC models. The interactive interface further allows
users to display chromosome regions deﬁned by physical
position, cytogenetic bands and sequence-tagged site (STS)
markers. In expression view, a total of 9785 genes can be
searched by using gene ID and gene description showing
individual gene data including 9162 genes displayed the
detail altered expression proﬁles of individual arrays repro-
cessed from re-analyzed Stanford HCC microarray data and
experimental data of the gene extracted from published
articles in PubMed. To demonstrate data reliability in our
database, AURKA, a gene reported to be up-regulated in
majority of HCC tissues (15), was selected as positive control
to perform semi-quantitative RT–PCR experiments in
45 pairs of HCC tissues. As indicated in Figure 2A, the
AURKA is highly up-regulated and the expression proﬁles
are almost identical to that of re-analyzed Stanford HCC
microarray data.
Selection and experimental validation of HCC genes
Stringent criteria were applied to select a set of 614 HCC
genes with signiﬁcant altered expression in HCC tissues
(Supplementary ﬁles in OncoDB.HCC). Among them,
446 genes were supported with more than two independent
studies in terms of altered expression including 145 concor-
dantly up-regulated, 176 concordantly down-regulated and
125 genes with mixed up-/down-regulated expression in
HCC tissues. The concordant expression of HCC genes
could serve as potential biomarkers for HCC diagnosis. In
addition, there were 234 genes with limited experimental
data in HCC and 256 genes located within recurrent chromo-
some aberration regions. All of them represent potential
targets for evaluation of their involvement in HCC tumorige-
nesis. In addition to AURKA, we further selected 30 out
of 234 genes with limited wet-lab experiments in HCC for
experimental validation. The validated results were demon-
strated in terms of concordant expression of gene up- or
down-regulation in 45 pairs of HCC tissues by RT–PCR
analysis and in comparison to 57 pairs of HCC samples of
re-analyzed Stanford HCC microarray data (Figure 2 and
supplementary ﬁles in OncoDB.HCC). A near perfect concor-
dant result except CKAP2 (96.7%, 29/30 genes) in altered
gene expression of HCC was obtained for 12 genes selected
based on three independent microarray and/or proteomic
reports and for 18 genes selected based on at least 2-fold
expression changes within 70% patients in re-analyzed
Stanford HCC microarray data.
Comparative mapping of HCC aberrant regions by
using rodent HCC models
To provide additional genetic support and reﬁne the HCC
loci for targeting cancer genes, the QTLs of rodent HCC
models identiﬁed via linkage studies were integrated into
OncoDB.HCC based on comparative maps of rodent gen-
omes in Ensembl. The results of 35 rodent HCC QTLs
were displayed according to the relative positions of human
chromosomes (Figure 1e). Comparative mapping of HCC
loci demonstrated that over 45% rodent QTLs (8 of the
12 mouse HCC QTLs and another 8 of the 23 rat HCC
QTLs) are located in the major aberrant loci of human
HCC (Table 1). Among 16 syntenic QTLs located in
12 HCC loci, 10 QTLs in 6 loci are potentially located in gain/
ampliﬁed regions and 6 QTLs in 6 loci are located in loss/
deleted regions. While the critical regions of HCC loci
existed in comparative genomes of human and rodents, the
HCC loci could be effectively narrowed down due to the
scrambled structure of genomes by comparing human and
rodent syntenic regions. We narrowed down two human
HCC loci to 2 Mb and another 6 HCC loci in between
4 and 10 Mb. Interestingly, the comparative mapping of
HCC loci allowed us to split three human major HCC aberra-
tion regions 1q, 4q and 8p21–23 into two smaller regions and
to conclude that at least two putative cancer genes located on
the same arm of above three human HCC chromosomes.
DISCUSSION
OncoDB.HCC is the ﬁrst attempt to establish a detail bioin-
formatic resource of one tumor genome by integrating
genomic data of chromosome aberrations, altered gene
expression, experimental data of genes in HCC tissues and
QTLs of rodent HCC models. Three important advantages
were revealed after data integration in OncoDB.HCC: First,
data integration from independent studies containing aberrant
consequences from levels of DNA, RNA and protein could
avoid possible pitfalls of data inconsistency from a single
D728 Nucleic Acids Research, 2007, Vol. 35, Database issuegenomic approach and provide lines of evidence to conclude
somatic aberrations. Second, due to the heterogeneity nature
of HCC tumorigenesis, successful gene validation in
OncoDB.HCC is critical for revealing signiﬁcantly altered
HCC genes for ‘signatures’ of somatic aberrations in dissect-
ing tumorigenic pathways and in clinical applications.
Finally, integrated genomic data in OncoDB.HCC could
narrow down and prioritize critical cancer genes and regions
Figure 1. The chromosome view of OncoDB.HCC: (a) indicated the chromosomal region displayed in cytogenetic position; (b) demonstrated the expression
intensity of genes along the physical positions of chromosome in terms of patient number by selecting gene expression cut-off value (default value ¼ 1) in re-
analyzed Stanford HCC microarray data; (c) showed the microarray/proteomic expression results from references; (d) indicated the positions of genes collected
from wet-lab experimental results; (e) revealed the comparative maps and the syntenic regions of mouse and rat HCC QTLs; (f) displayed the LOH frequencies
and minimum deletion regions (MDR) in positions of microsatellite markers; and (g) the cytogenetic locations of CGH results. All genes and markers were
annotated and hyperlinked against physical maps of genomes in Ensembl. The up-regulated genes and gain/amplified chromosomal regions were displayed in red
series color. In contrast, the down-regulated genes and loss/deleted chromosome regions were displayed in green series color.
Nucleic Acids Research, 2007, Vol. 35, Database issue D729for positional cloning and molecular studies of cancer genes
in HCC. The quality of integrated data in OncoDB.HCC
was experimentally supported by successful validation of
altered expression in selected genes with limited wet-lab
experimental studies in HCC. Therefore, the open access
OncoDB.HCC should serve as a valuable resource for HCC
research community.
FUTURE DEVELOPMENT
The OncoDB.HCC is the ﬁrst comprehensive integration
of cancer genomic data in one prevalent cancer with exp-
erimental validation and available freely to the research
community. The future perspectives for OncoDB.HCC are
to further integrate other newly emerging tumorigenic factors
such as epigenetic modulations, point mutations and
microRNA alterations in genome-wide aspects. In addition,
commercial available 300K or 500K high density SNP
chips are potentially useful to reveal high density novel
genomic alterations in HCC genome. In conclusion, the com-
prehensive OncoDB.HCC is an invaluable resource for better
understanding the tumorigenic mechanisms and developing
useful information in clinical applications. OncoDB.HCC
could serve as a bioinformatics resource that is applicable
to other prevalent human cancers for dissecting tumorigenic
pathways and the foundation of tumor systems biology.
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Figure 2. Experimental validation of representative genes in the HCC gene set. For each gene, the semi-quantitative RT–PCR results in 45 HCC pairs
are presented in gel images (left), in quantified expression profiles after normalization with b-actin expression as internal control (upper right) and in comparison
with expression profiles of the gene in re-analyzed Stanford HCC microarray data from expression view of OncoDB.HCC (lower right). (A) AURKA is a
positive control for HCC data process; (B and C) genes selected from criteria of significant expression difference in at lease three independent microarray/
proteomic studies; and (D–F) genes selected with criteria of at least 2-fold expression difference in at least 70% of paired arrays in re-analyzed Stanford HCC
microarray data.
Table 1. HCC loci and putative cancer genes by comparative mapping strategy
Human HCC Rodent QTL Putative cancer genes
Interval (Mb) LOH
a CGH
b Rat Mouse
Hcc1p 8 (59–67) 1 L (9) — Hcr1 CACHD1
Hcc1q1 49 (157–206) 4 G (25) Hcrem5 Hcrem6 Hcf2 Hcs7 COPA, ATF6, RGS5, GLUL, UBE2T, KISS1
Hcc1q2 6 (227–233) 2 G (25) — Hcs2
Hcc4q1 37 (52–89) 5 L (23) — Hcs5 IGJ, SLC4A4, ALB, AFM, CXCL2, PLAC8, PTPN13, ABCG2
Hcc4q2 6 (90–96) 3 L (22) Drh2a —
Hcc6p 4 (30–34) 0 G (14) — Hcf1 UBD, HSPA1B
Hcc8p1 2 (10–12) 1 L (22) Hcs7 — CTSB
Hcc8p2 2 (18–20) 2 L (22) Hcs4 — NAT2
Hcc8q 38 (97–135) 2 G (24) — Hfib1 LAPTM4B, PABPC1, ANGPT1, EIF3S6, EBAG9, ENPP2, ATAD2
Hcc9p 7 (0–7) 3 L (3) Drh1b —
Hcc11q 13 (58–71) — A (7), G (1) Hcs3 Drh1a — FEN1, FADS2, BAD, CDCA5
Hcc20q 29 (29–58) — G (10) — Hcs4 DNMT3B, E2F1, SRC, MYBL2, UBE2C, MMP9, CD40, AURKA
aNumber of references with significant LOH in the region defined by original authors.
bNumber of CGH references with significant alterations covered this region. G: CGH gain; L: CGH loss; and A: CGH amplification.
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